Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focused on targeted protein degradation, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Chief Medical Officer Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer Andrew Saik will engage in a fireside chat on Tuesday, December 3 at 2:30 p.m. ET in New York. The presentation will be accessible via live audio webcast on the company's website under the Events and Presentations section.
Arvinas (Nasdaq: ARVN), un'azienda biotech in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato la sua partecipazione alla 36a Conferenza Sanitaria Annuale di Piper Sandler. Il Direttore Medico Noah Berkowitz, M.D., Ph.D. e Il Direttore Finanziario Andrew Saik parteciperanno a una chiacchierata informale martedì, 3 dicembre alle 14:30 ET a New York. La presentazione sarà accessibile tramite un webcast audio dal vivo sul sito web dell'azienda nella sezione Eventi e Presentazioni.
Arvinas (Nasdaq: ARVN), una empresa biofarmacéutica en etapa clínica centrada en la degradación dirigida de proteínas, anunció su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El Director Médico Noah Berkowitz, M.D., Ph.D. y El Director Financiero Andrew Saik participarán en una charla informal el martes 3 de diciembre a las 2:30 p.m. ET en Nueva York. La presentación estará disponible a través de una transmisión de audio en vivo en el sitio web de la empresa en la sección de Eventos y Presentaciones.
Arvinas (Nasdaq: ARVN)는 표적 단백질 분해에 중점을 둔 임상 단계 생명공학 회사로 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 의료 담당 최고 책임자 Noah Berkowitz, M.D., Ph.D.와 재무 담당 최고 책임자 Andrew Saik은 12월 3일 화요일 오후 2시 30분 ET에 뉴욕에서 화상 대화에 참여할 것입니다. 발표는 회사 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 실시간 오디오 웹캐스트로 접근할 수 있습니다.
Arvinas (Nasdaq: ARVN), une entreprise biopharmaceutique en phase clinique axée sur la dégradation ciblée des protéines, a annoncé sa participation à la 36e Conférence Annuelle de Santé Piper Sandler. Le Directeur Médical Noah Berkowitz, M.D., Ph.D. et Le Directeur Financier Andrew Saik participeront à une discussion informelle le mardi 3 décembre à 14h30 ET à New York. La présentation sera accessible via un webinaire audio en direct sur le site web de l'entreprise dans la section Événements et Présentations.
Arvinas (Nasdaq: ARVN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die zielgerichtete Proteinabbau spezialisiert hat, gab seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler bekannt. Der medizinische Leiter Noah Berkowitz, M.D., Ph.D. und der Finanzvorstand Andrew Saik werden am Dienstag, den 3. Dezember um 14:30 Uhr ET in New York an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Live-Audio-Webcast auf der Unternehmenswebsite im Bereich Veranstaltungen und Präsentationen zugänglich sein.
- None.
- None.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York.
A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When is Arvinas (ARVN) presenting at the Piper Sandler Healthcare Conference?
Who will represent Arvinas (ARVN) at the Piper Sandler Healthcare Conference?
How can investors watch Arvinas's (ARVN) presentation at the Piper Sandler Conference?
What type of company is Arvinas (ARVN)?
